open access

Vol 15, No 1 (2010)
Published online: 2010-01-01
Submitted:
Get Citation

Thymoma: Results of treatment and role of radiotherapy

Marcin Hetnał, Krzysztof Małecki, Magdalena Wolanin, Stanisław Korzeniowski, Tomasz Walasek
DOI: 10.1016/j.rpor.2010.01.004
·
Rep Pract Oncol Radiother 2010;15(1):15-20.

open access

Vol 15, No 1 (2010)
Published online: 2010-01-01
Submitted:

Abstract

Purpose

The aim of this study is to assess results of treatment, factors influencing prognosis with regard to causes of failure and treatment tolerance in patients with thymoma.

Material and methods

Between 1966 and 2006, 63 patients with thymoma had been treated at the Centre of Oncology in Krakow. Patients were treated by means of different treatment modalities: surgery followed by radiotherapy (52%), radiotherapy alone (13%), chemoradiotherapy alone (15%), surgery followed by chemoradiotherapy (5%), surgery alone (5%) and others.

Results

The 10-year locoregional recurrence-free survival (LRRFS) was 79%, disease free survival (DFS) was 57% and overall survival (OS) was 57%. Masaoka stage was the only independent prognostic factor for LRRFS. Masaoka stage and method of radiotherapy delivery (higher photon energies), were independent prognostic factors for OS. For DFS, the independent prognostic factors were age, type of treatment (favoured surgery followed by radiotherapy or chemoradiotherapy), Masaoka stage and year of start of treatment. Most common reactions were lung fibrosis in 36% of patients (mainly asymptomatic in most patients), pneumonitis (9%) and oesophagitis (4%).

Conclusions

Surgery combined with radiotherapy and chemoradiotherapy and modern radiotherapy techniques are correlated with improvement of survival in patients with early stage thymoma.

Abstract

Purpose

The aim of this study is to assess results of treatment, factors influencing prognosis with regard to causes of failure and treatment tolerance in patients with thymoma.

Material and methods

Between 1966 and 2006, 63 patients with thymoma had been treated at the Centre of Oncology in Krakow. Patients were treated by means of different treatment modalities: surgery followed by radiotherapy (52%), radiotherapy alone (13%), chemoradiotherapy alone (15%), surgery followed by chemoradiotherapy (5%), surgery alone (5%) and others.

Results

The 10-year locoregional recurrence-free survival (LRRFS) was 79%, disease free survival (DFS) was 57% and overall survival (OS) was 57%. Masaoka stage was the only independent prognostic factor for LRRFS. Masaoka stage and method of radiotherapy delivery (higher photon energies), were independent prognostic factors for OS. For DFS, the independent prognostic factors were age, type of treatment (favoured surgery followed by radiotherapy or chemoradiotherapy), Masaoka stage and year of start of treatment. Most common reactions were lung fibrosis in 36% of patients (mainly asymptomatic in most patients), pneumonitis (9%) and oesophagitis (4%).

Conclusions

Surgery combined with radiotherapy and chemoradiotherapy and modern radiotherapy techniques are correlated with improvement of survival in patients with early stage thymoma.

Get Citation

Keywords

Thymoma; Radiotherapy; Surgery; Prognostic factors

About this article
Title

Thymoma: Results of treatment and role of radiotherapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 15, No 1 (2010)

Pages

15-20

Published online

2010-01-01

DOI

10.1016/j.rpor.2010.01.004

Bibliographic record

Rep Pract Oncol Radiother 2010;15(1):15-20.

Keywords

Thymoma
Radiotherapy
Surgery
Prognostic factors

Authors

Marcin Hetnał
Krzysztof Małecki
Magdalena Wolanin
Stanisław Korzeniowski
Tomasz Walasek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl